Adagio Therapeutics Funding: $130M Raised, Series B
Adagio Therapeutics has raised $130M in total funding. Latest round: Series B. Backed by Polaris Partners, Mithril Capital.
Adagio Therapeutics funding overview
Adagio Therapeutics has raised $130M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B. Investors on record include Polaris Partners, Mithril Capital, Fidelity Management & Research Company, OrbiMed, M28 Capital, GV and 2 others. 8 distinct backers are named across the disclosed rounds.
Adagio Therapeutics at a glance
Total raised
$130M
Latest round
Series B
Notable investors
Polaris Partners, Mithril Capital, Fidelity Management & Research Company, OrbiMed, M28 Capital, GV, Population Health Partners, Omega Funds
Frequently asked about Adagio Therapeutics funding
How much has Adagio Therapeutics raised?
Adagio Therapeutics has raised $130M in total disclosed funding across the rounds on record.
Who has invested in Adagio Therapeutics?
Polaris Partners, Mithril Capital, Fidelity Management & Research Company, OrbiMed, M28 Capital, GV are named among the investors backing Adagio Therapeutics.
What was the latest Adagio Therapeutics funding round?
The most recent disclosed round is a Series B.
Where is Adagio Therapeutics based?
No headquarters location is disclosed for Adagio Therapeutics.
We update the Adagio Therapeutics record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies and their backers are listed below.
